Pharmaceutical

Kyowa Kirin gets grant for monoclonal antibody inhibiting ccr1 activation by ccl15

Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.

Apr 11, 2024 - 00:00
Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.
Read the original article

Tags:

Previous Article

ADMA Biologics gets grant for treatment of upper respiratory tract infection wit...

Next Article

Dynamic-EC: An efficient dynamic erasure coding method for permissioned blockcha...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sildenafil citrate by XOMA Royalty for Female Hypoactiv...

Sep 10, 2024

AbbVie’s migraine medication Qulipta gets positive CHMP opinion

AbbVie’s migraine medication Qulipta gets positive CHMP...

Jun 23, 2023

STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

STAT+: Merck, Daiichi Sankyo to partner on targeted che...

Oct 20, 2023